GlassScriptPhysician profile
Kendra Sirolly
NPI 1144257502
$275.56
in general payments reported to CMS, 2019-2025
11 companies · $93.24 in 2025
The $93.24 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $78.08 · 2024: $104 · 2025: $93.24.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $276.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $275.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $56.37 | 2024-2025 | |
| Alk-Abello, INC | $36.28 | 2025 | Neffy |
| Glaxosmithkline, LLC. | $33.27 | 2023 | Bexsero |
| Corium, LLC | $28.91 | 2023-2024 | Azstarys |
| Phadia US INC. | $22.47 | 2025 | Immunocap |
| Sanofi Pasteur INC. | $19.31 | 2024 | |
| Merck Sharp & Dohme LLC | $16.96 | 2024 | Gardasil, Vaxelis, Gardasil 9 |
| Astrazeneca Pharmaceuticals LP | $16.75 | 2023 | Flumist Quadrivalent |
| Kaleo, INC. | $16.02 | 2024 | Auvi-Q |
| Seqirus USA INC | $14.72 | 2023 | Flucelvax Quadrivalent |
| Ironshore Pharmaceuticals INC. | $14.50 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kendra Sirolly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.